Ephraim Joseph Fuchs MD M.B.A.

Oncology•Baltimore, MD

Hematologic Oncology

Professor of Oncology, Johns Hopkins University School of Medicine; Associate Professor of Oncology

Join to View Full Profile

401 North Broadway StreetWeinberg BLDGBaltimore, MD 21287
Phone+1 410-955-8964
Fax+1 410-367-2194

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1991 - 1994
Johns Hopkins UniversityResidency, Internal Medicine, 1985 - 1988
Perelman School of Medicine at the University of PennsylvaniaClass of 1985

Certifications & Licensure

MD State Medical License 1988 - 2026
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer Start of enrollment: 1998 Jan 01
Completed
Phase 1
Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers Start of enrollment: 1998 Aug 01
Completed
Phase 2
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Start of enrollment: 1999 Dec 01
Completed
Phase 1
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Start of enrollment: 2004 Oct 01
Completed
Phase 2
Double Cord Versus Haploidentical (BMT CTN 1101) Start of enrollment: 2012 Jun 01
Completed
Phase 3
BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance Start of enrollment: 2014 Jan 07
Terminated
Phase 2
Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC) Start of enrollment: 2016 Mar 01
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic Transplantation.
Shannon R McCurdy, Scott R Solomon, Brian C Shaffer, Meilun He, Yung-Tsi Bolon
Transplantation and Cellular Therapy. 2025-10-01
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of m...
Jonathan A Webster, Madison Reed, Hua-Ling Tsai, Philip H Imus, Douglas B Smith
Haematologica. 2025-05-08
2 citations
Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma.
Nadeem Tabbara, Marianna Zahurak, Cole H Sterling, Iris Margalit Trutzer, Jaroslaw Jedrych
Blood Advances. 2025-03-11

Journal Articles

The European Society for Blood and Marrow Transplantation (EBMT) Consensus Recommendations for Donor Selection in Haploidentical Hematopoietic Cell Transplantation
Leo Luznik, Karen Ballen, Asad Bashey, Hillard M Lazarus, Bipin N Savani, Rizwan Romee, Ephraim J Fuchs, Nature

Press Mentions

The Bone-Marrow-Transplant RevolutionApril 23rd, 2024

Grant Support

Restoring T Cell Responses To Therapeutic Tumor VaccinesNational Cancer Institute2005–2009
Transplantation Of CD8+ T Cell-Depleted Peripheral Blood CellsNational Center For Research Resources2007
Allogeneic Lymphocyte Infusions To Treat Myeloid CancersNational Cancer Institute2006–2007
A Pilot Protocol To Determine The Effects Of Osmolar Stress In The ColonNational Center For Research Resources2006
Allogenic Graft Versus Tumor EffectNational Cancer Institute2001–2002
Immunotherapy Of Acute Lymphocytic LeukemiaNational Cancer Institute1996–1999
Activation Requirements Of Mature CD8+ T CellsNational Institute Of Allergy And Infectious Diseases1994–1996
Immunotherapy Of Acute Lymphocytic LeukemiaNational Cancer Institute1995

External Links

Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/ephraim-fuchs